Innovation Delivered: Resco Launches Autumn Update at resco.next 2019 Keynote
Resco, the leading provider of enterprise mobility solutions for Microsoft Dynamics 365 and Salesforce, has today officially introduced the Autumn Update 2019 at its annual resco.next conference in Rome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191024005635/en/
Innovation delivered - Resco (Photo: Business Wire)
The release stands among Resco’s most significant, as it marks a year since the company officially began the expansion of its product portfolio with Resco Inspections, followed by Resco Routes. It delivers major new capabilities to both, as well as to the company’s Mobile Business Apps Platform.
“Our Autumn Update further strengthens Resco’s commitment to innovation that fosters business productivity. It also brings a number of features that extend Resco products to smartwatches,” confirmed Miro Pomsar, CEO at Resco.
More details in a fraction of time
With new Resco Inspections features like Tagged image and Reusable answers, field teams can complete inspections faster and provide more details with context to the back office. Ultimately, helping to speed up any issue resolution and boosting client satisfaction and loyalty.
Importantly, the solution is also coming to smartwatches as part of the Autumn Update. Field professionals can now complete inspection forms from their wrist, utilizing voice control for an entirely hands-free experience.
More information on Resco Inspections Autumn Update 2019 available here.
Handling unexpected situations
The upgraded Location Monitor in Resco Routes enables users to take the guesswork out of planning and effectively manage unforeseen events. Details such as an unlimited number of tracked staff members, real-time travel direction & speed, time of the last stop, and progress through the day, provide the backbone for truly informed decisions.
More information on Resco Routes Autumn Update 2019 available here.
Let the AI do the work
Resco’s Mobile Business Apps Platform has been extended with functionality that improves the efficiency of both mobile users and system administrators.
The all-new AI image recognition is available across all Resco-based app. Mobile users can now utilize image recognition instead of search or barcode scanning. More complex scenarios are also possible when utilizing image recognition in form rules.
Furthermore, when using Resco Cloud as a backend, administrators can create new fields and entities on the system directly from Woodford – no need to switch between applications. And with new project item categories, they can bring structure and clarity even to complex mobile projects.
More information on Resco’s Mobile Business Apps Platform Autumn Update 2019 available here.
Industry Watch for deeper business insights
At resco.next the company also introduced its all-new Industry Watch initiative - a new concept of utilizing smartwatches to obtain more insights from staff outdoors and indoors. Making entire organizations smarter and more efficient.
“We are excited about this new venture and the road that lies ahead. In the following months, we’re going to continue our intensive research in the area of wearables. We would also like to engage our whole ecosystem into this initiative, including our partners.” Miro Pomsar explained.
More details regarding Resco’s new smartwatch initiative can be found here.
About Resco
Resco founded in 1999, is one of the global leaders in developing cross-platform mobile software solutions. The team of Resco professionals utilizes their knowledge to design products for corporate customers, developers, integrators, and end users. Today, Resco is utilized by 2,800+ corporate customers with more than 250,000 licensed users around the world. The cornerstone of Resco’s Mobile Business Apps Platform is the Woodford configuration and management tool, which together with the Resco mobile app form the base of all Resco products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005635/en/
Contact information
Resco Media Relations
Robert Feldmar
+421 2 209 020 17
communications@resco.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom